Lymphopenia during the COVID-19 infection: What it shows and what can be learned

Immunol Lett. 2020 Sep:225:31-32. doi: 10.1016/j.imlet.2020.06.013. Epub 2020 Jun 20.

Authors

Soheil Tavakolpour¹, Taha Rakhshandehroo¹, Erin X Wei², Mohammad Rashidian³

Affiliations

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, United States.
² Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, United States.
³ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, United States. Electronic address: mohammad_rashidian@dfci.harvard.edu.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus / pathogenicity*
CD4-Positive T-Lymphocytes / immunology
CD4-Positive T-Lymphocytes / metabolism
CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / metabolism
COVID-19
Coronavirus Infections / immunology*
Coronavirus Infections / mortality
Cytokines / metabolism
Disease Progression
Humans
Lymphopenia / mortality
Lymphopenia / virology*
Pandemics
Pneumonia, Viral / immunology*
Pneumonia, Viral / mortality
Prognosis
SARS-CoV-2
Severe Acute Respiratory Syndrome / immunology
Severe Acute Respiratory Syndrome / mortality
Severe Acute Respiratory Syndrome / virology*

Substances

Cytokines